The Effect of an App-based Intervention on Quality of Life in Patients With Endometriosis.
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Feb 6, 2025
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether using a special app can improve the quality of life for women who have endometriosis, a condition that often causes pain and discomfort. The researchers want to find out if the app helps lessen pain and makes daily life better for those affected. Participants will either use the app or not use it at all for six months, and they'll have check-ins after three and six months to see how they are doing. They will also fill out questionnaires to share how the app or the lack of it has impacted their lives.
To join the study, participants need to be women aged 18 or older who have been diagnosed with endometriosis or have symptoms that suggest they may have it. They should also have a smartphone, as the app will be used on this device. However, some women may not be eligible if they have recently had surgery, are pregnant or breastfeeding, or are planning to undergo certain treatments during the study. This trial is currently recruiting participants, and it offers a chance to explore a new way to manage endometriosis symptoms using technology.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent as documented by signature
- • Age 18 or older
- • Premenopausal status (menopause is defined as amenorrhea lasting one year or longer)
- • Endometriosis, confirmed by surgery or clinically suspected
- • Possession of a smartphone
- Exclusion Criteria:
- • Planned endometriosis surgery or planned hormonal therapy in the study period
- • Surgery and/or new hormonal therapy in the last three months
- • Malignant diseases
- • Pregnancy
- • Breastfeeding
- • Active desire for pregnancy in the study period
- • Fertility treatment
- • Simultaneous participation in other intervention studies
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Marietta Gulz, MD
Principal Investigator
University Hospital Bern, Insel Gruppe AG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported